$SPRY
ARS Pharmaceuticals, Inc. Stock $spry

$spry Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024034689 Filed on March 21, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$30.00K
YoY Change	-100.0%	-100.0%	-97.72%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$93.00K	$6.822M	$940.0K
YoY Change	-99.24%	-319.36%	-94.91%
% of Gross Profit
Research & Development	$5.234M	$3.404M	$20.27M
YoY Change	-20.12%	-155.17%	10.29%
% of Gross Profit
Depreciation & Amortization	$11.00K	$13.00K	$73.00K
YoY Change	-45.0%	-106.19%	-77.19%
% of Gross Profit
Operating Expenses	$13.19M	$10.23M	$67.55M
YoY Change	-29.58%	-141.6%	83.4%
Operating Profit	-$13.19M		-$67.52M
YoY Change	-29.5%		90.11%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$2.900M	$3.058M	$13.16M
YoY Change	-22.71%	268.43%	1477.34%
Pretax Income	-$10.29M	-$7.168M	-$54.37M
YoY Change	-31.2%	-126.31%	56.76%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$10.29M	-$7.168M	-$54.37M
YoY Change	-31.21%	-126.31%	56.75%
Net Earnings / Revenue			-181216.67%
Basic Earnings Per Share	-$0.11		-$0.57
Diluted Earnings Per Share	-$0.11	-$0.07	-$0.57
COMMON SHARES
Basic Shares Outstanding	96.50M	96.00M	95.22M
Diluted Shares Outstanding	96.49M		95.22M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$223.6M	$228.4M	$228.4M
YoY Change	-15.45%	-16.78%	-16.78%
Cash & Equivalents	$56.01M	$70.97M	$70.97M
Short-Term Investments	$167.6M	$157.4M	$157.4M
Other Short-Term Assets	$2.609M	$3.366M	$3.366M
YoY Change	-6.82%	2.0%	2.0%
Inventory		$0.00
Prepaid Expenses
Receivables		$0.00
Other Receivables	$280.0K	$178.0K
Total Short-Term Assets	$226.2M	$231.7M	$231.7M
YoY Change	-15.38%	-16.56%	-16.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$616.0K	$574.0K	$824.0K
YoY Change	5.48%	74.47%	3.0%
Goodwill
YoY Change
Intangibles		$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$528.0K	$638.0K	$638.0K
YoY Change	-81.79%		-78.73%
Total Long-Term Assets	$1.342M	$1.462M	$1.462M
YoY Change	-65.07%	-60.86%	-60.49%
TOTAL ASSETS
Total Short-Term Assets	$226.2M	$231.7M	$231.7M
Total Long-Term Assets	$1.342M	$1.462M	$1.462M
Total Assets	$227.6M	$233.2M	$233.2M
YoY Change	-16.08%	-17.14%	-17.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$839.0K	$759.0K	$1.475M
YoY Change	-67.48%	-54.25%	-57.86%
Accrued Expenses	$2.004M	$916.0K	$916.0K
YoY Change	-49.9%	-46.12%	-46.12%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.715M	$2.391M	$2.391M
YoY Change	-62.24%	-56.08%	-55.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$37.00K	$37.00K
YoY Change	-100.0%	-98.81%	-98.81%
Total Long-Term Liabilities	$0.00	$37.00K	$37.00K
YoY Change	-100.0%	-98.81%	-98.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.715M	$2.391M	$2.391M
Total Long-Term Liabilities	$0.00	$37.00K	$37.00K
Total Liabilities	$3.715M	$2.428M	$2.428M
YoY Change	-62.99%	-71.6%	-71.44%
SHAREHOLDERS EQUITY
Retained Earnings	-$141.6M	-$131.3M
YoY Change	54.08%	70.66%
Common Stock	$10.00K	$10.00K
YoY Change	11.11%	11.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$223.9M	$230.8M	$230.8M
YoY Change
Total Liabilities & Shareholders Equity	$227.6M	$233.2M	$233.2M
YoY Change	-16.08%	-17.14%	-17.13%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$10.29M	-$7.168M	-$54.37M
YoY Change	-31.21%	-126.31%	56.75%
Depreciation, Depletion And Amortization	$11.00K	$13.00K	$73.00K
YoY Change	-45.0%	-106.19%	-77.19%
Cash From Operating Activities	-$6.710M	-$17.41M	-$59.27M
YoY Change	-46.01%	-252.68%	47.88%
INVESTING ACTIVITIES
Capital Expenditures	$83.00K	-$95.00K	$175.0K
YoY Change	-56.99%	-80.21%	-12.06%
Acquisitions
YoY Change
Other Investing Activities	-$8.430M	$25.95M	-$87.01M
YoY Change	-92.43%
Cash From Investing Activities	-$8.513M	$26.04M	-$87.18M
YoY Change	-92.37%	5325.0%	43709.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	258.0K	1.809M	6.899M
YoY Change	-80.44%	-99.04%	-96.38%
NET CHANGE
Cash From Operating Activities	-6.710M	-17.41M	-59.27M
Cash From Investing Activities	-8.513M	26.04M	-87.18M
Cash From Financing Activities	258.0K	1.809M	6.899M
Net Change In Cash	-14.97M	10.44M	-139.5M
YoY Change	-87.8%	-94.81%	-192.75%
FREE CASH FLOW
Cash From Operating Activities	-$6.710M	-$17.41M	-$59.27M
Capital Expenditures	$83.00K	-$95.00K	$175.0K
Free Cash Flow	-$6.793M	-$17.31M	-$59.44M
YoY Change	-46.18%	-245.72%	47.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001671858
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	ecd	Trd Arr Duration TrdArrDuration	P479D
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39756
CY2023	dei	Entity Registrant Name EntityRegistrantName	ARS Pharmaceuticals, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-1489190
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	11682 El Camino Real
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 120
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2023	dei	City Area Code CityAreaCode	858
CY2023	dei	Local Phone Number LocalPhoneNumber	771-9307
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	SPRY
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96501554
CY2023Q2	dei	Entity Public Float EntityPublicFloat	381800000
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70971000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	210518000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	157389000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	63863000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3366000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3319000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	231726000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	277700000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	250000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	445000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	574000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	329000
CY2023Q4	us-gaap	Other Assets OtherAssets	638000
CY2022Q4	us-gaap	Other Assets OtherAssets	2961000
CY2023Q4	us-gaap	Assets Assets	233188000
CY2022Q4	us-gaap	Assets Assets	281435000
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	178000
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	16000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2154000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4931000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	237000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	230000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	283000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2391000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5444000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	251000
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2854000
CY2023Q4	us-gaap	Liabilities Liabilities	2428000
CY2022Q4	us-gaap	Liabilities Liabilities	8549000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96414963
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96414963
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93943316
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93943316
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	10000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	9000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	362004000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	349408000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	49000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	407000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-131303000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-76938000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	230760000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	272886000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	233188000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	281435000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1316000
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1796000
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2144000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20266000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18376000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	940000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	603000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47284000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18456000
CY2023	us-gaap	Operating Expenses OperatingExpenses	67550000
CY2022	us-gaap	Operating Expenses OperatingExpenses	36832000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-67520000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-35516000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13155000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	974000
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments	0
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-140000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54365000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-34682000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-358000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	407000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54723000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34275000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	95215322
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	95215322
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39956043
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	39956043
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-31269000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	76039000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	255761000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	223000
CY2022	spry	Stock Issued During Period Value Stock Options Exercised Under Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedUnderEmployeeStockPurchasePlan	564000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5843000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-34275000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	272886000
CY2023	spry	Stock Issued During Period Value Stock Options Exercised Under Employee Stock Purchase Plan StockIssuedDuringPeriodValueStockOptionsExercisedUnderEmployeeStockPurchasePlan	6900000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9347000
CY2023	spry	Removal Of Retrospective Insurance Policy Acquired In The Merger RemovalOfRetrospectiveInsurancePolicyAcquiredInTheMerger	-3650000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-54723000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	230760000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-54365000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-34682000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	9235000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5843000
CY2023	spry	Research And Development Expense Acquired In Process Cost ResearchAndDevelopmentExpenseAcquiredInProcessCost	0
CY2022	spry	Research And Development Expense Acquired In Process Cost ResearchAndDevelopmentExpenseAcquiredInProcessCost	1056000
CY2023	us-gaap	Depreciation Depreciation	73000
CY2022	us-gaap	Depreciation Depreciation	34000
CY2023	spry	Amortization And Accretion Net AmortizationAndAccretionNet	-6878000
CY2022	spry	Amortization And Accretion Net AmortizationAndAccretionNet	285000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	140000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1435000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1186000
CY2023	spry	Increase Decrease In Donation Of Equipment IncreaseDecreaseInDonationOfEquipment	-30000
CY2022	spry	Increase Decrease In Donation Of Equipment IncreaseDecreaseInDonationOfEquipment	0
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	162000
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-143000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2777000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10285000
CY2023	spry	Operating Right Of Use Assets And Lease Liabilities OperatingRightOfUseAssetsAndLeaseLiabilities	-12000
CY2022	spry	Operating Right Of Use Assets And Lease Liabilities OperatingRightOfUseAssetsAndLeaseLiabilities	33000
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3137000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1316000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59266000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40078000
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	272005000
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	185000000
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	175000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	199000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87180000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-199000
CY2023	spry	Cash Proceeds From The Merger Net Of Transaction Costs CashProceedsFromTheMergerNetOfTransactionCosts	0
CY2022	spry	Cash Proceeds From The Merger Net Of Transaction Costs CashProceedsFromTheMergerNetOfTransactionCosts	198843000
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6899000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	570000
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	8681000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6899000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	190732000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-139547000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	150455000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	210518000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60063000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	70971000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	210518000
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	76039000
CY2023	spry	Short Term Investments Assumed In Merger ShortTermInvestmentsAssumedInMerger	0
CY2022	spry	Short Term Investments Assumed In Merger ShortTermInvestmentsAssumedInMerger	63473000
CY2023	spry	Prepaid Expense And Other Current Assets Assumed In The Merger PrepaidExpenseAndOtherCurrentAssetsAssumedInTheMerger	0
CY2022	spry	Prepaid Expense And Other Current Assets Assumed In The Merger PrepaidExpenseAndOtherCurrentAssetsAssumedInTheMerger	4404000
CY2023	spry	Accounts Payable And Accrued Liabilities Assumed In The Merger AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger	0
CY2022	spry	Accounts Payable And Accrued Liabilities Assumed In The Merger AccountsPayableAndAccruedLiabilitiesAssumedInTheMerger	12017000
CY2023	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1	0
CY2022	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1	223000
CY2023	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	0
CY2022	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	366000
CY2023	spry	Removal Of Retrospective Prepaid Insurance Acquired In Merger RemovalOfRetrospectivePrepaidInsuranceAcquiredInMerger	3649000
CY2022	spry	Removal Of Retrospective Prepaid Insurance Acquired In Merger RemovalOfRetrospectivePrepaidInsuranceAcquiredInMerger	0
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	91000
CY2023	spry	Capital Expenditures Reclassed From Prepaid Expenses And Other Current Assets CapitalExpendituresReclassedFromPrepaidExpensesAndOtherCurrentAssets	174000
CY2022	spry	Capital Expenditures Reclassed From Prepaid Expenses And Other Current Assets CapitalExpendituresReclassedFromPrepaidExpensesAndOtherCurrentAssets	0
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="footnote1" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nat</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ure of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc. (“ARS”, “ARS Pharma” or the “Company”) is focused on the development of ARS-1 (brand name </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">), a proprietary product candidate for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions including anaphylaxis. The Company incorporated in Delaware in January 2016 and is located in San Diego, California. The Company has a wholly owned subsidiary, ARS Pharmaceuticals Operations, Inc., incorporated in Delaware in August 2015, through which it conducts substantially all its operations. ARS Pharmaceuticals Operations, Inc. has a wholly owned subsidiary in Ireland, ARS Pharmaceuticals IRL, Limited, to facilitate the filing of regulatory approval for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in European countries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Merger Transaction</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 8, 2022 (the “Closing Date”), Silverback Therapeutics, Inc., a Delaware corporation (“Silverback”), now known as ARS Pharmaceuticals, Inc., completed its reverse merger (the “Merger”) with privately-held ARS Pharma, in accordance with the terms of the agreement and plan of merger and reorganization, dated July 21, 2022, as amended on August 11, 2022 and October 25, 2022 (the “Merger Agreement”), whereby Sabre Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and wholly-owned subsidiary of Silverback, merged into ARS Pharma, with ARS Pharma surviving as Silverback’s wholly-owned subsidiary. ARS Pharma was renamed ARS Subsidiary, Inc., and then subsequently renamed ARS Pharmaceuticals Operations, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At the effective time of the Merger (the “Effective Time”), each share of ARS Pharma common stock outstanding immediately prior to the Effective Time, after giving effect to the automatic conversion of all shares of preferred stock of ARS Pharma into shares of ARS Pharma common stock immediately prior to the Effective Time (excluding shares held as treasury stock by ARS Pharma or held or owned by Silverback, Merger Sub or any subsidiary of Silverback or ARS Pharma and dissenting shares), was automatically converted into the right to receive shares of Silverback common stock equal to the exchange ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1819</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. At the completion of the Merger, the prior ARS Pharma equityholders owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and the prior Silverback equityholders owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">38</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the combined company, in each case on a fully diluted basis using the treasury stock method and excluding out-of-money options of Silverback.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Merger was accounted for as a reverse recapitalization, with ARS Pharma being treated as the acquirer for accounting purposes. Pursuant to the Merger Agreement, Silverback changed its name to ARS Pharmaceuticals, Inc., and changed its corporate ticker symbol on the Nasdaq Global Market to “SPRY”. See discussions of the transactions in connection with the Merger at </span><a href="#footnote3"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 3 - Merger and Related Transactions</span></a><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred net operating losses since its inception and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">131.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023. The Company had cash, cash equivalents, and short-term investments of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">228.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of December 31, 2023 and has not generated positive cash flows from operations. To date, the Company has funded its operations primarily with proceeds from the Merger, the issuance of convertible preferred stock, payments earned under collaboration agreements and bank debt. The Company’s currently available cash, cash equivalents, and short-term investments as of December 31, 2023 are sufficient to meet its anticipated cash requirements for at least the 12 months following the date these financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From August 5, 2015 (inception) through December 31, 2023, the Company has devoted substantially all of its efforts to developing intellectual property, conducting product development and clinical trials, raising capital, and building infrastructure. The Company has a limited operating history, and the sales and income potential of the Company’s business and market are unproven. If the Company does not successfully commercialize any product candidates for which it receives regulatory approval, it will be unable to generate recurring product revenue or achieve profitability. Management expects operating expenses to increase for the foreseeable future and there can be no assurance that the Company will ever achieve profitability, or if achieved, that it will be sustained on a continuing basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s ability to raise additional capital may be adversely impacted should the global economic conditions worsen or as a result of further disruptions to, and volatility in, the credit and financial markets in the United States, including bank failures, future health epidemics or pandemics, geopolitical actions or other macroeconomic factors. If such further disruption occurs, the Company could experience an inability to access additional capital. If the Company is not able to secure adequate additional funding, it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reduction in Force</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On September 19, 2023, the FDA issued a CRL regarding our NDA for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. On September 29, 2023, we initiated a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% reduction in force (“RIF”) in order to conserve our cash resources and manage operating expenses until the anticipated PDUFA target action date in the middle of the second half of 2024. We provided severance payments, continuation of group health insurance coverage, and other benefits for a specified period to the affected employees. We incurred costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for termination benefits resulting from the RIF, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million remains accrued for as of December 31, 2023.</span></p>
CY2023Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.20
CY2023Q3	us-gaap	Severance Costs1 SeveranceCosts1	600000
CY2023Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	100000
CY2023	spry	Stockholdersequitynotestocksplitexchangeratio Stockholdersequitynotestocksplitexchangeratio	1.1819
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to revenue recognized for its collaboration agreements, accruals for research and development expenses and valuation of equity awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue and expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality financial institutions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews its financial instruments </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">portfolio on a quarterly basis to determine if any unrealized losses have resulted from a credit loss or other factors. As part of the review, management considers factors such as historical experience, market data, issuer-specific factors, and current economic conditions. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11543081
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12119667
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	400000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	400000
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	700000
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1124000
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	771000
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	904000
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1539000
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	686000
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	796000
CY2023Q4	spry	Prepaid Development Costs PrepaidDevelopmentCosts	380000
CY2022Q4	spry	Prepaid Development Costs PrepaidDevelopmentCosts	0
CY2023Q4	spry	Capitalized Software Implementation Costs CapitalizedSoftwareImplementationCosts	163000
CY2022Q4	spry	Capitalized Software Implementation Costs CapitalizedSoftwareImplementationCosts	0
CY2023Q4	us-gaap	Other Receivables OtherReceivables	109000
CY2022Q4	us-gaap	Other Receivables OtherReceivables	213000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3366000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3319000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	695000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	377000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	121000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	48000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	574000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	329000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	617000
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	0
CY2022Q4	spry	Restricted Stock Units Granted And Outstanding RestrictedStockUnitsGrantedAndOutstanding	10651
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	0
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2940000
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	21000
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	21000
CY2023Q4	us-gaap	Other Assets OtherAssets	638000
CY2022Q4	us-gaap	Other Assets OtherAssets	2961000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	759000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1659000
CY2023Q4	spry	Accrued Clinical Expenses AccruedClinicalExpenses	515000
CY2022Q4	spry	Accrued Clinical Expenses AccruedClinicalExpenses	609000
CY2023Q4	spry	Accrued Compensation AccruedCompensation	315000
CY2022Q4	spry	Accrued Compensation AccruedCompensation	447000
CY2023Q4	spry	Accrued Development Expenses AccruedDevelopmentExpenses	190000
CY2022Q4	spry	Accrued Development Expenses AccruedDevelopmentExpenses	133000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	174000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	908000
CY2023Q4	spry	Accrued Pre Commercialization Marketing Related Expenses Current AccruedPreCommercializationMarketingRelatedExpensesCurrent	42000
CY2022Q4	spry	Accrued Pre Commercialization Marketing Related Expenses Current AccruedPreCommercializationMarketingRelatedExpensesCurrent	0
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	4000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	174000
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	155000
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1001000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	2154000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	4931000
CY2020Q3	spry	Initial Transaction Price InitialTransactionPrice	11800000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3137000
CY2023	spry	Contract With Customer Liability In Process Research And Development Expense ContractWithCustomerLiabilityInProcessResearchAndDevelopmentExpense	-3107000
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	30000
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	In October 2021, the Company entered into a 38-month noncancelable lease for its current headquarters location consisting of 4,047 rentable square feet of office space in San Diego, California. Under the terms of the agreement, there is no option to extend the lease, and the Company is subject to additional charges for common area maintenance and other costs
CY2023	us-gaap	Lessee Operating Sublease Option To Extend LesseeOperatingSubleaseOptionToExtend	there is no option to extend the lease
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P14M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	245000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	42000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	287000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	274000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	237000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37000
CY2023	spry	In Licensingandsupply Textblock InLicensingandsupplyTextblock	<p id="note8" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In-Licensing and Supply</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement with Aegis</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2018, the Company entered into a License Agreement (the “Aegis Agreement”) with Aegis Therapeutics, LLC (“Aegis”). Under the Aegis Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable, rights to certain proprietary Aegis technology, patent rights and know-how to develop and commercialize epinephrine products. The Company utilizes this technology for the development of its lead product candidate, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. As consideration for the license, the Company paid an upfront license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which was recorded in research and development expenses in the consolidated statement of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is required to make aggregate milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million upon achievement of certain regulatory and commercial milestones. The regulatory milestone payments under the Aegis Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. The Company made a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment to Aegis upon the achievement of a regulatory milestone during 2019, and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment to Aegis upon the FDA’s acceptance of the Company’s NDA submission for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which occurred in the third quarter of 2022. The Company may be required to pay royalties based on annual net product sales in the low to mid-single digits on its or its sublicensees’ net sales of the Licensed Products (as defined in the Aegis Agreement) on a country-by-country and product-by-product basis.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is responsible for reimbursing Aegis for patent costs incurred in connection with prosecuting and maintaining patent rights that are specific to epinephrine or epinephrine products. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> expenses recognized in connection with legal patent fees for the years ended December 31, 2023 and 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company may terminate the Aegis Agreement with 30 days written notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In conjunction with the Aegis Agreement, the Company also entered into a Supply Agreement (the “Supply Agreement”) with Aegis that allows the Company to purchase materials for preclinical, development and commercial use at predetermined prices. The Company may elect to have Aegis supply minimum quantities but there are no minimum or maximum purchase obligations under the Supply Agreement unless this election is made. The parties may terminate the Supply Agreement at any time by mutual agreement. In addition, the parties may terminate the Supply Agreement in the event of certain breaches of the Supply Agreement or upon the earlier of the expiration or termination of the Aegis Agreement or June 2028. The Supply Agreement term may be extended by mutual written agreement. Under the Supply Agreement, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in expense was recognized in the years ended December 31, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Manufacturing Agreement with Renaissance</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2020, the Company entered into a manufacturing agreement with Renaissance Lakewood, LLC (“Renaissance”), which was subsequently amended in July 2023 (the “Renaissance Agreement”). Pursuant to the Renaissance Agreement, Renaissance agreed to manufacture for, and provide to the Company, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">nasal unit dose sprays (“Renaissance Products”). The Company is obligated to provide Renaissance with certain supplies to manufacture the Renaissance Products and to purchase from Renaissance a mid double-digit percentage of the Company’s annual aggregate Renaissance Product requirements in the E.U., and a high double-digit percentage of the Company’s annual aggregate Renaissance Product requirements in the U.S. The Renaissance Agreement contains conventional commercial pharmaceutical manufacturing provisions including certain minimum purchase amounts to be determined in the future based on forecast needs and minimum batch size projections. The Company may also request Renaissance to perform certain services related to the Renaissance Product, for which the Company will pay reasonable compensation to Renaissance.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The initial term of the Renaissance Agreement commenced on September 9, 2020 and continues (a) for Renaissance Product designated for commercial sale in the U.S. until the earlier of the fifth anniversary of the (i) target U.S. launch date and (ii) the initial U.S. launch date (“U.S. Initial Term”), and (b) for Renaissance Product designated for commercial sale in the E.U. and other countries, the earlier of the fifth anniversary of (i) the target E.U. launch date and (ii) the initial E.U. launch date (“E.U. Initial Term”), in each case unless earlier terminated by one of the parties. The U.S. Initial Term and E.U. Initial Term automatically renew for successive two-year terms (“Renewal Term”). Either party may elect not to renew the U.S. Renewal Term and/or the E.U. Renewal Term by providing the requisite prior notice to the other party. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the Company has not submitted a regulatory filing for any Renaissance Product in the U.S. on or before June 30, 2022, (b) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before the target U.S. launch date, (c) the authorization and approval representing more than a targeted number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (d) the Company decided in its sole discretion</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	spry	Common Stock Options Granted And Outstanding CommonStockOptionsGrantedAndOutstanding	11493481
CY2022Q4	spry	Common Stock Options Granted And Outstanding CommonStockOptionsGrantedAndOutstanding	12063560
CY2023Q4	spry	Restricted Stock Units Granted And Outstanding RestrictedStockUnitsGrantedAndOutstanding	4144
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y3M7D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	25078000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8500000
CY2023Q4	spry	Common Stock Capital Shares Reserved For Future Awards Or Option Grants CommonStockCapitalSharesReservedForFutureAwardsOrOptionGrants	6220866
CY2022Q4	spry	Common Stock Capital Shares Reserved For Future Awards Or Option Grants CommonStockCapitalSharesReservedForFutureAwardsOrOptionGrants	3373801
CY2023Q4	spry	Warrantstopurchasecommonstock Warrantstopurchasecommonstock	45456
CY2022Q4	spry	Warrantstopurchasecommonstock Warrantstopurchasecommonstock	45456
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17763947
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	15493468
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9235000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5843000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	22700000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M4D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12063560
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.07
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4749600
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.03
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2422636
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.76
CY2023	spry	Stock Issued During Period Shares Stock Options Forfeited StockIssuedDuringPeriodSharesStockOptionsForfeited	2897043
CY2023	spry	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice	15.06
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11493481
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.32
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M20D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	25078000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	7502931
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.86
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1200000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.31
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4500000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2700000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.953
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.913
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-11416000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7283000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-22000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-21000
CY2023	spry	Income Tax Reconciliation Officers Compensation IncomeTaxReconciliationOfficersCompensation	745000
CY2022	spry	Income Tax Reconciliation Officers Compensation IncomeTaxReconciliationOfficersCompensation	195000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	749000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	290000
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1179000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	624000
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-88000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	257000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11211000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7186000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16127000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	8252000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4143000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2964000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	7322000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3746000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1498000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2279000
CY2023Q4	spry	Deferred Tax Assets Contract Liability DeferredTaxAssetsContractLiability	0
CY2022Q4	spry	Deferred Tax Assets Contract Liability DeferredTaxAssetsContractLiability	661000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	66000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	104000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	29156000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	18006000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	53000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	94000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	59000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	155000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	112000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	249000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29044000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	17757000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29044000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	17757000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11300000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	76200000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2500000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1520000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1147000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	951000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	475000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	373000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2946000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1520000
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2022Q2	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.05
CY2023	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	400000
CY2022	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	100000
CY2023Q4	ecd	Trd Arr Ind Name TrdArrIndName	Brian Dorsey
CY2023Q4	ecd	Trd Arr Ind Title TrdArrIndTitle	Chief Operating Officer
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	true
CY2023Q4	ecd	Trd Arr Termination Date TrdArrTerminationDate	December 8, 2023
CY2023Q4	ecd	Trd Arr Securities Agg Avail Amt TrdArrSecuritiesAggAvailAmt	340000
CY2023Q4	spry	Trd Arr Expiration Date TrdArrExpirationDate	March 31, 2025
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	true
CY2023Q4	ecd	Trd Arr Adoption Date TrdArrAdoptionDate	December 8, 2023
CY2023Q4	spry	Rule10 B51 Arr Modified Flag Rule10B51ArrModifiedFlag	true

Files In Submission

Name	View Source	Status
0000950170-24-034689-index-headers.html	Edgar Link	pending
0000950170-24-034689-index.html	Edgar Link	pending
0000950170-24-034689.txt	Edgar Link	pending
0000950170-24-034689-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img76005383_0.jpg	Edgar Link	pending
img76005383_1.jpg	Edgar Link	pending
img76005383_10.jpg	Edgar Link	pending
img76005383_11.jpg	Edgar Link	pending
img76005383_12.jpg	Edgar Link	pending
img76005383_13.jpg	Edgar Link	pending
img76005383_2.jpg	Edgar Link	pending
img76005383_3.jpg	Edgar Link	pending
img76005383_4.jpg	Edgar Link	pending
img76005383_5.jpg	Edgar Link	pending
img76005383_6.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
img76005383_7.jpg	Edgar Link	pending
img76005383_8.jpg	Edgar Link	pending
img76005383_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
spry-20231231.htm	Edgar Link	pending
spry-20231231.xsd	Edgar Link	pending
spry-ex10_9.htm	Edgar Link	pending
spry-ex21_1.htm	Edgar Link	pending
spry-ex23_1.htm	Edgar Link	pending
spry-ex31_1.htm	Edgar Link	pending
spry-ex31_2.htm	Edgar Link	pending
spry-ex32_1.htm	Edgar Link	pending
spry-ex97_1.htm	Edgar Link	pending
spry-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SPRY
ARS Pharmaceuticals, Inc. Stock $spry

2024 Q1 Form 10-K Financial Statement

#000095017024034689 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SPRY ARS Pharmaceuticals, Inc. Stock $spry

2024 Q1 Form 10-K Financial Statement

#000095017024034689 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SPRY
ARS Pharmaceuticals, Inc. Stock $spry